Journal article
Net clinical benefit of dabigatran vs. warfarin in venous thromboembolism: analyses from RE-COVER®, RE-COVER™ II, and RE-MEDY™
Abstract
The direct oral anticoagulants, e.g., dabigatran etexilate (DE), are effective and well tolerated treatments for venous thromboembolism (VTE). Net clinical benefit (NCB) is a useful concept in weighing potential benefits against potential harm of comparator drugs. The NCB of DE vs. warfarin in VTE treatment was compared. Post-hoc analyses were performed on pooled data from the 6-month RE-COVER® and RE-COVER™ II trials, and data from the …
Authors
Feuring M; Schulman S; Eriksson H; Kakkar AJ; Schellong S; Hantel S; Schueler E; Kreuzer J; Goldhaber SZ
Journal
Journal of Thrombosis and Thrombolysis, Vol. 43, No. 4, pp. 484–489
Publisher
Springer Nature
Publication Date
May 2017
DOI
10.1007/s11239-017-1479-z
ISSN
0929-5305